White Paper: Linear DNA amplicons as a novel cancer vaccine strategy
PCR tests arrive to trace cotton in garments
LAURA PÉREZ | 7 MARCH, 2022 If PCR tests already exist to detect Covid, why not do PCR’s to trace cotton? That was the question MeiLin Wan, vice president of textiles at Applied DNA Sciences, posed to BOF. Of course, making such a utopia a reality requires overcoming some challenges to achieve an effective method [...]
Organic Cotton Expert Slams ‘Certification Charade’
By Crispin Argento, March 3, 2022 The recent New York Times exposé “That Organic Cotton T-Shirt May Not Be as Organic as You Think’” should not be misinterpreted as an affront to farmers who choose to grow organically or the organic agricultural philosophy—in fact, it can and should be viewed as quite the opposite. Following what [...]
Applied DNA Announces Closing of $4.2 Million Registered Direct Offering
STONY BROOK, N.Y. February 24, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with an institutional investor of 1,496,400 shares of common stock (or common stock equivalents) at a price of $2.80 [...]
APDN Announces Pricing of $4.2 Million Registered Direct Offering
STONY BROOK, N.Y. - February 22, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock (or common [...]
Beefing Up Cancer Treatments, With A Vaccine In Sight
Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed [...]
APDN, EvviVax Announce Publication of Positive Preclinical Data for Linear DNA™ Platform Approach to Cancer Immunotherapy
STONY BROOK, N.Y. and ROME, ITALY – February 17, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its program development partner, EvviVax, S.R.L. ("Evvivax"), today announced the publication of a manuscript detailing [...]
APDN FQ1’22 Financial Results Feature Record Quarterly Revenues
STONY BROOK, N.Y. February 10, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021. “Applied DNA had an excellent [...]
APDN Schedules FQ1’22 Financial Results Call and Webcast
STONY BROOK, N.Y. – February 3, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, [...]